Navigation Links
Cumberland Pharmaceuticals Announces Joey Jacobs Has Joined Its Board of Directors
Date:1/6/2011

NASHVILLE, Tenn., Jan. 6, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) is pleased to announce the addition of Joey Jacobs to its Board of Directors.

A healthcare veteran with more than 30 years of industry experience, Mr. Jacobs is the former Chairman, President and Chief Executive Officer of Nashville-based Psychiatric Solutions, Inc. (PSI), which he co-founded in 1997 and grew into a $2 billion behavioral healthcare system before the company's sale to Universal Health Services in 2010.

Prior to founding PSI, Mr. Jacobs spent 21 years at Hospital Corporation of America (HCA) where he served in various capacities, including President of the company's Tennessee Division.

In addition to serving as Chairman of the Nashville Healthcare Council, he is a director for the Federation of American Hospitals, the National Association of Psychiatric Health Systems and the Monroe Carell, Jr. Children's Hospital at Vanderbilt.

"We are honored to welcome Joey to our Board of Directors," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "Throughout his career, he has maintained a strong focus on quality and growth while creating significant value for stakeholders. His hospital industry perspective, entrepreneurial insight and experience building a successful public healthcare company will be of tremendous value to Cumberland."

Mr. Jacobs' appointment is effective January 1, 2011. He will serve as a Class I Director and hold office until Cumberland's 2011 annual shareholder meeting, at which time the company's Class I Directors will be elected for a term expiring in 2014.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's product portfolio includes Acetadote® for the treatment of acetaminophen poisoning, Caldolor®, the first injectable treatment for pain and fever approved in the United States, and Kristalose®, a prescription laxative. Cumberland is dedicated to providing innovative products which improve quality of care for patients. For more information on Cumberland Pharmaceuticals, please visit the Company's website at www.cumberlandpharma.com.


'/>"/>
SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
3. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
4. Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
5. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
6. Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010
7. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
8. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
9. Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
10. Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
11. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor ... market is expected to grow at a CAGR of 27.1% ... 38.7% in the second half of the forecast period. The market ... to 2027. The market is estimated at $1,058 million in 2016, ... ...
(Date:1/19/2017)... 2017 James Gilbart ... Haematology, 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... Published recently in a supplement to European Oncology ... an article by James Gilbart and ...
(Date:1/19/2017)... , Jan. 19, 2017   Science Exchange , ... to announce that the first five replication studies ... have been published in eLife today. Despite intense ... the first practical evaluation of reproducibility rates that ... studies. Unlike other assessments of reproducibility, the results ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Remote Medical Technologies ... impressive transportable capabilities with their iMedHD2™ Portable Teleultrasound System. Compatible ... technology that delivers HD, dynamic, streaming ultrasound images and video to one or ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... provided a new $11,250,000 senior credit facility to Sunrise, Florida-based Management Health Systems, ... were used to facilitate a recapitalization of MedPro led by Harren Equity Partners. ...
(Date:1/19/2017)... ... January 19, 2017 , ... Workrite Ergonomics announced ... , The Tranquility privacy panel system was designed to deliver the ideal blend ... reduce noise and provide the visual privacy required to maintain concentration levels and ...
(Date:1/19/2017)... Ashland, VA (PRWEB) , ... January 19, 2017 , ... ... planning services to the eastern Virginia region, is inaugurating a charity event to honor ... community. , While on duty last year, Chad Phillip Dermyer and his fellow officers ...
(Date:1/19/2017)... Norwalk, CT (PRWEB) , ... January 19, 2017 ... ... board certified Reproductive Endocrinologists at Reproductive Medicine Associates of Connecticut (RMACT) have ... Hurwitz, Dr. Cynthia Murdock and Dr. Shaun Williams have each been chosen by ...
Breaking Medicine News(10 mins):